Catch up on the top stories in optometry during the week of March 10-March 14.
The FDA has accepted the New Drug Application (NDA) submitted by Sydnexis for SYD-101, a low-dose atropine drop indicated for myopia management, with a Prescription Drug User Fee Act (PDUFA) target action date set for October 23, 2025. If approved, the atropine drop will be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States.